First Light Asset Management Increases Stake in ADMA Biologics

Biotechnology firm ADMA Biologics sees institutional investment grow as it expands its plasma-derived biologics portfolio.

Mar. 16, 2026 at 10:05am

Got story updates? Submit your updates here. ›

First Light Asset Management LLC increased its stake in ADMA Biologics Inc. (NASDAQ:ADMA) by 12.3% in the third quarter, according to a recent SEC filing. The firm now owns 1,069,233 shares of the biotechnology company's stock, making it ADMA Biologics' 25th largest institutional investor and accounting for approximately 1.5% of First Light Asset Management's investment portfolio.

Why it matters

ADMA Biologics is a biopharmaceutical company focused on developing and commercializing specialty plasma-derived biologics to treat immunodeficiencies and infectious diseases. The increase in institutional investment, particularly from a firm like First Light Asset Management, signals growing confidence in ADMA's business model and product pipeline.

The details

According to the SEC filing, First Light Asset Management acquired an additional 117,137 shares of ADMA Biologics during the third quarter, bringing its total holdings to 1,069,233 shares. This represents about 0.45% of ADMA's outstanding shares. The investment firm cited ADMA's progress in expanding its portfolio of plasma-derived therapies as a key factor behind the increased stake.

  • First Light Asset Management increased its ADMA Biologics holdings in the third quarter of 2026.

The players

First Light Asset Management LLC

An investment management firm that focuses on biotechnology and other healthcare-related companies.

ADMA Biologics Inc.

A biopharmaceutical company that develops and commercializes specialty plasma-derived biologics to treat immunodeficiencies and infectious diseases.

Got photos? Submit your photos here. ›

The takeaway

The increased investment from First Light Asset Management underscores the growing institutional interest in ADMA Biologics as the company continues to expand its portfolio of plasma-derived therapies. This signals confidence in ADMA's ability to capitalize on the growing demand for specialized biologic treatments.